Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
企業コードNTRA
会社名Natera Inc
上場日Jul 02, 2015
最高経営責任者「CEO」Mr. Steven Leonard (Steve) Chapman
従業員数4424
証券種類Ordinary Share
決算期末Jul 02
本社所在地13011 Mccallen Pass
都市AUSTIN
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号78753
電話番号16502499090
ウェブサイトhttps://www.natera.com/
企業コードNTRA
上場日Jul 02, 2015
最高経営責任者「CEO」Mr. Steven Leonard (Steve) Chapman
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし